Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roginolisib Combined With Obinutuzumab Followed by Venetoclax in Refractory/Relapsed CLL
NCT07847957Phase 2Not yet recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2027
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of roginolisib in chronic lymphocytic leukemia (CLL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose-Limiting Toxicities at 2 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
roginolisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07847957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847957.